Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
GROWTH
ZolgensmaⓇ maintains leading share in patients with SMA <2 years
of age¹; Q4 growth impacted by prior year prevalent boluses
Sales evolution
USD m, % cc
Ex-US
US
+5%
-5%
342
1,351
1,370
309
224
882
936
209
118
100
469
434
Q4 2021
Q4 2022
FY 2021
FY 2022
1. Based on US data.
28 Investor Relations | Q4 2022 Results
zolgensma®
Markets mainly incident patient population
Maintaining leader share (>90% US) in <2 years
Q4 sales decline due to prior year prevalent boluses
in ex-US markets (Europe/Canada)
FY sales USD 1.4bn (+5% cc)
Continued efforts to increase newborn screening
ex-US (45% in Europe; >99% in US)
IT development on track - Ph3 STEER and
STRENGTH enrolling
NOVARTIS | Reimagining MedicineView entire presentation